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sics and Nephropathy concerning the relationship between 3. Elseviers MM, Waller I, Nenov D, et al: Evaluation of diagnostic
criteria for analgesic nephropathy in patients with end-stage renalnonphenacetin-combined analgesics and nephropathy [1].
failure: Results of the ANNE study. Nephrol Dial Transplant 10:808–Although we appreciate the attempts of government and 814, 1995
industry to gather evidence-based insight in this field, we 4. Elseviers MM, De Schepper A, Corthouts B, et al: High diagnostic
performance of CT scan for analgesic nephropathy in patients withwere surprised by several statements. In particular, the
incipient to severe renal failure. Kidney Int 48:1316–1323, 1995Committee considered as their first scientific issue, “quality
of the diagnostic criteria for ‘analgesic nephropathy’ in To the Editor: I was fascinated by the paper by Fein-
pathological and radiological manifestations.” This im- stein et al in the December issue of Kidney International
portant issue was handled in two sentences. “The morpho- [1]. In animal studies, the incidence and severity of exper-
logic finding of papillary calcification can arise from other imental renal papillary necrosis (RPN) induced by non-
conditions and is not specific for AAN. For these reasons, phenacetin-containing analgesics [“aspirin plus (paracet-the identification criteria for AAN should be reappraised
amol or salicylamide) plus caffeine,” 38 to 75% RPN] andwith scientific methods to validate the diagnostic proce-
that by phenacetin-containing analgesics (17 to 70% RPN)dure.” In the period 1990 to 1995, we developed diagnostic
are similar [2]. In Australia, clinical and pathologic studiescriteria for analgesic nephropathy based on renal imaging
showed that the addictive abuse of nonphenacetin con-criteria. We performed a Belgian study [2], a European
taining combined analgesics over a period of more than 8study [3], and a computed tomography (CT) scan valida-
years was associated with ongoing analgesic nephropathytion study [4]. We found that, using a CT scan without
(AN) and renal failure [3]. These data do not support thecontrast, the combination of small kidneys with either
conclusion that “sufficient evidence is absent to associatebumpy contours or papillary calcification showed a high
nonphenacetin combined analgesics with nephropathy.”sensitivity and specificity for the diagnosis of analgesic
The Committee has questioned the specificity of thenephropathy. In the meantime, these criteria were used
diagnosis of AN. The clinical diagnosis of this conditionin studies performed in the Czech Republic, Hungary,
is firm and includes a reliable history of analgesic abusePoland, the United Kingdom, Belgium, and a National
and radiologic demonstration of RPN (criteria and refer-Institutes of Health–supported study. Hence, we never
ences in [4]). RPN is usually not a histologic diagnosis.focused solely on papillary calcifications. Moreover, none
This review article asserts that “the association [ofof our papers related to these criteria was added to the
AN] with phenacetin is established.” All experimentalreferences in the review article, despite the fact that they
and clinical data suggest that the association of AN iswere sent to the Committee’s chairman at his request.
with “(aspirin or antipyrine) plus phenacetin plus caf-It cannot be denied that the evidence for nephrotoxic-
feine,” and not phenacetin alone. Alone, the nephrotox-ity of phenacetin-containing analgesic mixtures is more
impressive than for the others. However, the parties join- icity of the combined analgesic mixtures is greater than
ing this debate intend to undermine every argument aspirin, which is greater than phenacetin. The medullary
pointing to the potential nephrotoxicity of nonphenace- toxicity of phenacetin is likely due to paracetamol, the
tin-combined analgesics. We wish the Committee success major immediate metabolite of phenacetin, because par-
in setting up a study to prove what they want to be proven, acetamol and not phenacetin concentrates in the medulla
that is, that all combined analgesics on the market are [reviewed in 2–4].
harmless to the kidney. We wonder, who will benefit The restriction of all combined analgesics in Australia
from such a study? We doubt it will be our patients. in 1979 has led to a decrease in new patients with AN
commencing dialysis, from 21% in 1979 to 5% in 1999,
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and in patients 45 to 64 years of age, from 30 to 9 patientsEdegem/Antwerpen, Belgium
per million population per year.
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Fig. 1. Yearly incidence of new dialysis patients. Abbreviations are: (h), analgesic nephropathy (AN) patients; (j), other patients.
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sic-associated nephropathy (AAN) in our area in Flan-
ders, Belgium [2]. It is well known that renal functionREFERENCES
may stabilize when the abuse of phenacetin combined1. Feinstein AR, Heinemann LAJ, Curhan GC, et al: Relationship
between nonphenacetin combined analgesics and nephropathy: A analgesics is stopped [3].
review. Kidney Int 58:2259–2264, 2000 Until 1972, the most abused compound analgesic con-
2. Nanra RS: Experimental renal effects of analgesics, rat, in Mono-
tained 280 mg phenacetin, 370 mg phenazone, 75 mggraphs on Pathology of Laboratory Animals, Urinary System (2nd
ed.), edited by Jones TC, Hard GC, Mohr U, New York, Springer- caffeine, and 10 mg chinin aethylcarbonicum. In 1972,
Verlag, 1997, pp 289–299 phenacetin was replaced by phenazone-salicylate. The
3. Nanra RS, Stuart-Taylor J, De Leon AH, White KH: Analgesic
new, abused composition included 225 mg phenazone,nephropathy: Etiology, clinical syndrome, and clinicopathologic cor-
relations in Australia. Kidney Int 13:79–92, 1978 260 mg phenazone-salicylate, 90 mg caffeine, and 30 mg
4. Kincaid-Smith P, Nanra RS: Lithium-induced and analgesic-induced chinin aethylcarbonicum. Since 1989, it has become a sin-
renal diseases, in Diseases of the Kidney (5th ed.), edited by Schrier
gle analgesic using 500 mg paracetamol and 50 mg caf-RW, Gottschalk CW, Boston, Little, Brown and Company, 1993,
pp 1099–1130 feine.
In 1988, we reported that the substitution of phenacetin
by phenazone-salicylate 16 years earlier did not change the
To the Editor: In the December 2000 issue of Kidney yearly incidence of new dialysis patients with AAN [2].
International, the Ad Hoc Committee of the Interna- In 1997, a declining incidence of new dialysis patients
tional Study Group on Analgesics and Nephropathy with AAN was described, 90% of whom were women,
stated that there is insufficient evidence to associate non- but with a greater acceptance rate [4]. The declining
phenacetin-combined analgesics with nephropathy [1]. incidence ultimately reached statistical significance at the
end of 1998 (Fig. 1). This statistical significance occurred
26 years after the withdrawal of phenacetin and 9 years
after the withdrawal of nonphenacetin combined analge-Ó 2001 by the International Society of Nephrology
